Q3 2025 saw a 7% sales decline and a significant operating loss, mainly due to a SEK 18.5 million impairment. The Combinostics acquisition and regulatory approvals in Asia strengthen future prospects, with a return to growth expected in Q4.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.